Skip to content
value.today

Yield10 Bioscience, Inc.

YTENUnlisted company
$3 Mlast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
—
For year ending December-2023
Net income
$-14 M
SEC filing
Employees
—

About Yield10 Bioscience, Inc.

Yield10 Bioscience (formerly Metabolix, Inc.) is a company developing new technologies to achieve improvements in crop yield to enhance global food security.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

Yield10 Bioscience, Inc. timeline

6 events, 1992–2019
  1. 1992
  2. 🏁
    · approximate
    Founded by Anthony J Sinskey
  3. 2002
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2006
  6. 🔔
    · approximate
    Initial public offering on Nasdaq
  7. 📈
    · approximate
    Listed on Nasdaq as YTEN
  8. 2017
  9. ✎
    Renamed Yield10 Bioscience, Inc.
    Formerly Metabolix Inc.
  10. 2019
  11. 💰
    Record revenue of $1 million
    FY2019, the highest of the 5 years on record.

Events of Yield10 Bioscience, Inc. from Wikidata, SEC EDGAR, the company record and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

More about Yield10 Bioscience, Inc.

Acquisitions and changes
Delisted: the exchange removed its shares from listing (Form 25-NSE) on 19 July 2024.

Market cap history

$0 M$6 M$11 M$17 M$23 M20232024

World rank over time

▼ down 2,643 places since 2022
2022-01-07: #30514#30,51420222022-12-25: #31510#31,51020222023-07-30: #31136#31,13620232024-01-05: #33157#33,1572024

Rank in USA: #5,380 (Jan 2022) · #5,580 (Dec 2022) · #5,363 (Jul 2023) · #4,685 (Jan 2024)

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2016: revenue $1M, net income $-8M$1MFY16Fiscal year ending Dec 2017: revenue $1M, net income $-9M$1MFY17Fiscal year ending Dec 2018: revenue $1M, net income $-9M$1MFY18Fiscal year ending Dec 2019: revenue $1M, net income $-13M$1MFY19Fiscal year ending Dec 2020: revenue $1M, net income $-10M$1MFY20Fiscal year ending Dec 2021: revenue $1M, net income $-11M$1MFY21Fiscal year ending Dec 2022: revenue $0M, net income $-14M$0MFY22Fiscal year ending Dec 2023: revenue —, net income $-14M—FY23
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2023——$-14M$-14M—
Dec 2022$0M-26.2%$-13M$-14M-3015.6%
Dec 2021$1M-23.8%$-12M$-11M-1808.2%
Dec 2020$1M-1.2%$-10M$-10M-1276.3%
Dec 2019$1M+44.6%$-9M$-13M-1600.0%
Dec 2018$1M-40.4%$-9M$-9M-1639.3%
Dec 2017$1M-19.0%$-9M$-9M-1000.0%
Dec 2016$1M—$-10M$-8M-655.2%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2023$-10M$0M$-10M$-1.82—
Dec 2022$-11M$0M$-12M$-2.76—
Dec 2021$-9M$0M$-9M$-2.33—
Dec 2020$-9M$0M$-9M$-4.30—
Dec 2019$-9M$0M$-9M$-35.50—
Dec 2018$-9M$0M$-9M$-36.99—
Dec 2017$-8M$0M$-8M$-3.29—
Dec 2016$-14M$1M$-15M——

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Mar 2023: revenue $0M, net income $-4M$0MMar ’23Three months to Jun 2023: revenue —, net income $-4M—Jun ’23Three months to Sep 2023: revenue —, net income $-4M—Sep ’23Three months to Dec 2023 (from the annual report): revenue —, net income $-3M—Dec ’23Three months to Mar 2024: revenue $0M, net income $-2M$0MMar ’24Three months to Jun 2024: revenue $0M, net income $-3M$0MJun ’24

Latest quarter to Jun 2024: revenue $0M, net income $-3M. Lighter bars: fourth quarters worked out from the annual report.

SEC filings

Official filings of Yield10 Bioscience, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-14 M
Net income
$-14 M

For year ending December-2023 · source: SEC filing

Balance sheet

Total assets
$4 M
Total liabilities
$6 M
Total equity
$-2 M

As of December-2023

Brands of Yield10 Bioscience, Inc. (1)#

Bioplastic 1

  • Bioplastic · since 2006

Source: Wikidata. Brands whose Wikidata item names Yield10 Bioscience, Inc. (or a subsidiary of it) as owner, maker or parent organization; each brand's page links to its item

Insider trading at Yield10 Bioscience, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
22
since
Yield10 Bioscience, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Kristi SnellVP Research and CSOShares withheld for tax-877$1.500$1 K6,999Form 4
filed Charles B. HaaserVP Finance and CAOShares withheld for tax-731$1.500$1 K5,949Form 4
filed Lynne H. BrumVP Planning and CommunicationsShares withheld for tax-731$1.500$1 K5,867Form 4
filed Oliver P. PeoplesPresident and CEO, DirectorShares withheld for tax-1,463$1.500$2 K12,634Form 4
filed Robert L. Van NostrandDirectorGrant or award+11,924——48,635Form 4
filed Anthony J. SinskeyDirectorGrant or award+20,561——64,274Form 4
filed Richard William HamiltonDirectorGrant or award+41,118——72,598Form 4
filed Kristi SnellVP Research and CSOGrant or award+120,000$0.300$36 K129,022Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Yield10 Bioscience, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2024-11-29
68
1 days to cover

Stock splits: 1-for-24 reverse split ; 1-for-24 reverse split ; 10-for-1 split ; 1-for-6 reverse split

Bankruptcy filing: (8-K)

Fails to deliver

  • : 745 shares at $0.66

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Yield10 Bioscience, Inc. scorecard#

Passes 0 of the 7 checks that could be worked out. Fiscal year 2023.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-1.82 vs -2.76Diluted EPS -1.82 in fiscal 2023 against -2.76 the year before (report's currency).
    • ✗Net income higher than five years earlier-$14 M-$14 M in fiscal 2023 against -$9 M in 2018.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$14 MNet income -$14 M in fiscal 2023.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2023.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health0 of 2
    • ✗Short-term assets cover short-term liabilities0.3×Current ratio 0.29 at the end of fiscal 2023.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2023.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year61.7%Diluted shares up 61.7% in fiscal 2023.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Agriculture Related, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Yield10 Bioscience, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Yield10 Bioscience, Inc.: statements by fiscal year
PeriodTrendFY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016FY 2015to Dec 31, 2015FY 2014to Dec 31, 2014
Income statement
Revenue0.10.50.60.80.80.60.91.21.4r2.8
Cost of revenue————————0.71.5
Selling, general and administrative6.26.26.15.04.65.1r5.65.77.2r11
Total costs and expenses141412109.49.9r101114r30
Operating income−14−13−12−9.6−8.6−9.3r−9.3−10−12r−27
Interest and finance income————0.10.2————
Other non-operating income (expense)−0.00.00.7−0.5−4.60.1r−0.1−0.00.10.1
Income before tax−14−13−11−10−13−9.2r−9.4−10−12r−29
Income tax00.20.00.1−0.300−1.100
Income from continuing operations——————−9.4−9.2−12r−27
Income from discontinued operations——————01.6−11r−2.8
Net income attributable to shareholders−14−14−11−10−13−9.2r−9.4−7.6−24−30
Earnings per share, basic-1.82-2.76-2.33-4.30-35.50-36.99r-3.29-2.73r-0.95-2.88r
Earnings per share, diluted-1.82-2.76-2.33-4.30-35.50-36.99r-3.29——-0.48
Shares, weighted average (basic)7.94.94.72.4—————61
Shares, weighted average (diluted)7.94.94.72.40.40.2r3.32.8r2561
Balance sheet
Cash and cash equivalents1.12.45.33.45.43.0147.31220
Short-term investments02.0116.35.72.70——0
Receivables—00.20.10.10.10.10.10.20.0
Inventory———————00.1r0.6
Other current assets0.30.60.40.50.50.40.30.41.70.8
Current assets1.45.01710126.4157.915r22
Property, plant and equipment0.50.80.90.91.21.41.51.70.1r0.5
Right-of-use (leased) assets1.72.02.42.73.14.8————
Long-term investments0000000———
Total assets3.98.120151713r17111723
Accounts payable1.20.10.10.10.30.10.10.10.10.3
Current liabilities4.91.61.71.82.21.6r2.42.83.94.2
Lease liabilities (non-current)1.52.12.7r3.23.65.6————
Total liabilities6.43.74.45.0217.3r3.44.44.14.3
Retained earnings−414−400−386−375−365−352r−343−333−326−302
Shareholders' equity−2.54.4169.5−4.15.7r146.41319
Total liabilities and equity3.98.120151713r17111723
Shares outstanding0.5r4.94.93.30.90.3r9.12.8r27r23r
Cash-flow statement
Depreciation and amortization0.30.30.20.20.20.20.20.50.30.5
Share-based compensation1.61.91.70.70.71.21.40.82.12.3
Cash from operating activities−10−11−9.3−8.7−8.7−8.8−8.2−14r−22−25
Capital expenditure−0.0−0.2−0.2−0.1−0.1−0.0−0.0−0.8−0.7−0.2
Cash from investing activities1.98.5−4.6−0.6−3.0−2.8−0.0r9.8−0.612
Shares issued—0125.3140130——
Cash from financing activities6.9−0.0167.3140.115−0.3r1525
Exchange-rate effect on cash−0.0−0.1−0.0−0.0−0.0−0.0−0.0———
Change in cash−1.3−3.01.9−2.12.4−117.1———
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2024. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Yield10 Bioscience, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Bankruptcy or receivershipFiling
  • Delisting noticeFiling
  • Delisting noticeFiling
  • Auditor changedFiling
  • Delisting noticeFiling
  • Auditor changedFiling

Bankruptcy or receivership 1 · Delisting notice 5 · Auditor changed 2 · Restructuring 2 · Directors and officers 5 · Material agreement 6 · Agreement ended 1 · New debt 1 · Bylaws or fiscal year changed 2 · Shareholder vote 4 · Results announced 3

Yield10 Bioscience, Inc.: events reported to the SEC
FiledWhat happenedFiling
Bankruptcy or receivershipRestructuringDirectors and officers8-K
Shareholder vote8-K
Material agreementShareholder vote8-K
Directors and officers8-K
Directors and officersMaterial agreement8-K
Material agreementNew debt8-K
Agreement ended8-K
Material agreement8-K
Bylaws or fiscal year changed8-K
Directors and officersShareholder vote8-K
Delisting notice8-K
Results announced8-K
Bylaws or fiscal year changed8-K
Shareholder vote8-K
Results announced8-K
Delisting notice8-K
Material agreement8-K
Material agreement8-K/A
Auditor changed8-K
Delisting notice8-K
Auditor changed8-K
RestructuringDirectors and officers8-K
Delisting notice8-K
Results announced8-K
Delisting notice8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Dec 6, 2024

Acquisitions and funding#

2 private funding rounds before listing

Private share sales · funding history

Private share sales of Yield10 Bioscience, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2017$2 MNo. 2$2 to $10 million11equity, optionsSEC
Aug 2014$25 MNo. 1$10 to $50 million27equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at Yield10 Bioscience, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
45
2012–2023
Latest
—
2023-11-30
Yield10 Bioscience, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2023············—
2016······45·····45
2014············—
2012············—
Yield10 Bioscience, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
65% of workforceRestructuring planSEC 8-K“("Yield10" or the "Company") approved the full or partial furlough of approximately 65% of its workforce, most of whom are located in the Company's U.S. facility.”Filing
45 peopleRestructuring planSEC 8-K“As part of the restructuring, Metabolix will discontinue its biopolymer operations and eliminate approximately 45 positions in its biopolymer operations and corporate organization,…”Filing
Not statedRestructuring planSEC 8-KCompany-wide planFiling
Not statedRestructuring planSEC 8-KCompany-wide planFiling

Source: State WARN notices and SEC 8-K item 2.05

How Yield10 Bioscience, Inc. compares in Agriculture Related

  • Revenue growth-26.2% · higher than 10% of 21

Peer comparison · Agriculture Related

CompanyMarket capP/ENet marginRev. growth
Yield10 Bioscience, Inc.🇺🇸$3 M——-26.2%
Corteva, Inc.🇺🇸$51.2 B67.4×4.3%+2.9%
Nutrien Ltd.🇨🇦$33.0 B14.6×8.4%+3.5%
Qinghai Salt Lake Industry Co., Ltd🇨🇳$22.2 B18.1×54.7%—
Zangge Holding Company🇨🇳$18.1 B32.4×——
CF Industries Holdings, Inc.🇺🇸$17.7 B6.9×32.2%+19.3%
Saudi Arabian Fertilizers Company🇸🇦$15.5 B13.5×33.0%-17.3%
Yara International ASA🇳🇴$11.4 B8.3×8.8%—
Shandong Hualu-Hengsheng Chemical Co., Ltd.🇨🇳$8.4 B17.5×10.7%—

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 5, 2024 (last known)
Annual results:
For year ending December-2023
Balance sheet:
As of December-2023
Profile updated:
Nov 14, 2026

Figures from SEC filing, Wikidata, value.today research, Wikipedia; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Yield10 Bioscience, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Yield10 Bioscience, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Yield10 Bioscience, Inc.? Suggest a correction